Bobak R. Azamian Sells 8,534 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak R. Azamian sold 8,534 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $427,638.74. Following the completion of the transaction, the chief executive officer now owns 53,635 shares of the company's stock, valued at approximately $2,687,649.85. The trade was a 13.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock traded up $2.39 during midday trading on Monday, reaching $52.36. 1,101,887 shares of the stock traded hands, compared to its average volume of 643,190. The firm has a fifty day moving average price of $48.59 and a two-hundred day moving average price of $45.64. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -13.74 and a beta of 1.05. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. On average, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Remove Ads

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter worth about $25,000. GF Fund Management CO. LTD. bought a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $44,000. R Squared Ltd acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter worth approximately $53,000. FMR LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after acquiring an additional 3,537 shares in the last quarter. Finally, Quarry LP acquired a new position in shares of Tarsus Pharmaceuticals during the fourth quarter valued at approximately $166,000. Institutional investors own 90.01% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on TARS. Guggenheim reaffirmed a "buy" rating and issued a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. HC Wainwright reaffirmed a "buy" rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Barclays dropped their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Jefferies Financial Group raised their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Finally, Oppenheimer upped their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $63.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.